{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:05:12Z","timestamp":1792976712555,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-19362-3","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T09:15:37Z","timestamp":1760087737000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prognostic relevance of TROP2 expression in patients with non-small cell lung cancer receiving immunotherapy"],"prefix":"10.1038","volume":"15","author":[{"given":"Naohito","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Takei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoichi","family":"Kaira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisao","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Shiono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ou","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuto","family":"Mouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Hamda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kagamu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"19362_CR1","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.2147\/DDDT.S489234","volume":"18","author":"M Li","year":"2024","unstructured":"Li, M. et al. Current status and future prospects of TROP-2 ADCs in lung cancer treatment. Drug Des. Devel. Ther. 18, 5005\u20135021. https:\/\/doi.org\/10.2147\/DDDT.S489234 (2024).","journal-title":"Drug Des. Devel. Ther."},{"key":"19362_CR2","doi-asserted-by":"publisher","first-page":"4678","DOI":"10.1200\/JCO.23.00059","volume":"41","author":"T Shimizu","year":"2023","unstructured":"Shimizu, T. et al. First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate Datopotamab Deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01. J. Clin. Oncol. 41, 4678\u20134687. https:\/\/doi.org\/10.1200\/JCO.23.00059 (2023).","journal-title":"J. Clin. Oncol."},{"key":"19362_CR3","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1200\/JCO-24-01544","volume":"43","author":"MJ Ahn","year":"2025","unstructured":"Ahn, M. J. et al. TROPION-Lung01 trial investigators. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 Study. J. Clin. Oncol. 43, 260\u2013272. https:\/\/doi.org\/10.1200\/JCO-24-01544 (2025).","journal-title":"J. Clin. Oncol."},{"key":"19362_CR4","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/pin.12911","volume":"70","author":"R Mito","year":"2020","unstructured":"Mito, R. et al. Clinical impact of TROP2 in non-small lung cancers and its correlation with abnormal p53 nuclear accumulation. Pathol. Int. 70, 287\u2013294. https:\/\/doi.org\/10.1111\/pin.12911 (2020).","journal-title":"Pathol. Int."},{"key":"19362_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00428-010-0930-8","volume":"457","author":"H Kobayashi","year":"2010","unstructured":"Kobayashi, H. et al. Expression of the GA733 gene family and its relationship to prognosis in pulmonary adenocarcinoma. Virchows Arch. 457, 69\u201376. https:\/\/doi.org\/10.1007\/s00428-010-0930-8 (2010).","journal-title":"Virchows Arch."},{"key":"19362_CR6","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3892\/ol.2013.1368","volume":"6","author":"A Jiang","year":"2013","unstructured":"Jiang, A. et al. Expression and clinical significance of the Trop-2 gene in advanced non-small cell lung carcinoma. Oncol. Lett. 6, 375\u2013380. https:\/\/doi.org\/10.3892\/ol.2013.1368 (2013).","journal-title":"Oncol. Lett."},{"key":"19362_CR7","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.2217\/fon-2023-0230","volume":"19","author":"BP Levy","year":"2023","unstructured":"Levy, B. P. et al. TROPION-Lung08: Phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC. Future Oncol. 19, 1461\u20131472. https:\/\/doi.org\/10.2217\/fon-2023-0230 (2023).","journal-title":"Future Oncol."},{"key":"19362_CR8","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1158\/1078-0432.CCR-23-2566","volume":"30","author":"A Bessede","year":"2024","unstructured":"Bessede, A. et al. TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non-small cell lung cancer. Clin. Cancer Res. 30, 779\u2013785. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2566 (2024).","journal-title":"Clin. Cancer Res."},{"key":"19362_CR9","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.4161\/cbt.26341","volume":"14","author":"X Wang","year":"2013","unstructured":"Wang, X. et al. Chemotherapy agents-induced immunoresistance in lung cancer cells could be reversed by trop-2 inhibition in vitro and in vivo by interaction with MAPK signaling pathway. Cancer Biol. Ther. 14, 1123\u20131132. https:\/\/doi.org\/10.4161\/cbt.26341 (2013).","journal-title":"Cancer Biol. Ther."},{"key":"19362_CR10","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.21037\/atm-22-5976","volume":"10","author":"Y Wen","year":"2022","unstructured":"Wen, Y. et al. A literature review of the promising future of TROP2: A potential drug therapy target. Ann. Transl. Med. 10, 1403. https:\/\/doi.org\/10.21037\/atm-22-5976 (2022).","journal-title":"Ann. Transl. Med."},{"key":"19362_CR11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s41016-017-0096-1","volume":"3","author":"B Li","year":"2017","unstructured":"Li, B. et al. Risk factors of brain metastasis of lung squamous cell carcinoma: A retrospective analysis of 188 patients from single center. Chin. Neurosurg. J. 3, 32. https:\/\/doi.org\/10.1186\/s41016-017-0096-1 (2017).","journal-title":"Chin. Neurosurg. J."},{"key":"19362_CR12","doi-asserted-by":"publisher","first-page":"28725","DOI":"10.18632\/oncotarget.15647","volume":"8","author":"K Inamura","year":"2017","unstructured":"Inamura, K. et al. Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes. Oncotarget 8, 28725\u201328735. https:\/\/doi.org\/10.18632\/oncotarget.15647 (2017).","journal-title":"Oncotarget"},{"key":"19362_CR13","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1001\/jamaoncol.2022.4002","volume":"8","author":"AK Ganti","year":"2021","unstructured":"Ganti, A. K. et al. Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US. JAMA Oncol. 8, 1645\u20131652. https:\/\/doi.org\/10.1001\/jamaoncol.2022.4002 (2021).","journal-title":"JAMA Oncol."},{"key":"19362_CR14","doi-asserted-by":"publisher","first-page":"e1480","DOI":"10.1093\/oncolo\/oyae168","volume":"29","author":"D Morgenstern-Kaplan","year":"2024","unstructured":"Morgenstern-Kaplan, D. et al. Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors. Oncologist 29, e1480\u2013e1491. https:\/\/doi.org\/10.1093\/oncolo\/oyae168 (2024).","journal-title":"Oncologist"},{"key":"19362_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ygyno.2024.04.022","volume":"187","author":"Y Chiba","year":"2024","unstructured":"Chiba, Y. et al. TROP-2 expression and the tumor immune microenvironment in cervical cancer. Gynecol. Oncol. 187, 51\u201357. https:\/\/doi.org\/10.1016\/j.ygyno.2024.04.022 (2024).","journal-title":"Gynecol. Oncol."},{"key":"19362_CR16","doi-asserted-by":"publisher","first-page":"9004","DOI":"10.1200\/JCO.2023.41.16_suppl.9004","volume":"41","author":"Y Goto","year":"2023","unstructured":"Goto, Y. et al. TROPIONLung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non\u2013small cell lung cancer (aNSCLC). J. Clin. Oncol. 41, 9004. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.9004 (2023).","journal-title":"J. Clin. Oncol."},{"key":"19362_CR17","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s12672-024-01261-0","volume":"15","author":"J Lai","year":"2024","unstructured":"Lai, J. et al. Identification of biomarker associated with TROP2 in breast cancer: Implication for targeted therapy. Discov. Oncol. 15, 413. https:\/\/doi.org\/10.1007\/s12672-024-01261-0 (2024).","journal-title":"Discov. Oncol."},{"key":"19362_CR18","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1159\/000534169","volume":"102","author":"O Yamaguchi","year":"2024","unstructured":"Yamaguchi, O. et al. Clinical utility of inflammatory and nutritious index as therapeutic prediction of nivolumab plus ipilimumab in advanced non-small cell lung cancer. Oncology 102, 271\u2013282. https:\/\/doi.org\/10.1159\/000534169 (2024).","journal-title":"Oncology"},{"key":"19362_CR19","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1200\/JCO.22.01503","volume":"41","author":"JR Brahmer","year":"2023","unstructured":"Brahmer, J. R. et al. Five-year survival outcomes with Nivolumab plus Ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in Checkmate 227. J. Clin. Oncol. 41, 1200\u20131212. https:\/\/doi.org\/10.1200\/JCO.22.01503 (2023).","journal-title":"J. Clin. Oncol."},{"key":"19362_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumour: Revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026 (2009).","journal-title":"Eur. J. Cancer"},{"key":"19362_CR21","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.3390\/ijms24043618","volume":"24","author":"C Mahiat","year":"2023","unstructured":"Mahiat, C., Bihin, B. & Duplaquet, F. Systemic inflammation\/nutritional status scores are prognostic but not predictive in metastatic non-small-cell lung cancer treated with first-line immune checkpoint inhibitors. Int. J. Mol. Sci. 24, 3618. https:\/\/doi.org\/10.3390\/ijms24043618 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"19362_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.lungcan.2021.06.024","volume":"159","author":"RD Seban","year":"2021","unstructured":"Seban, R. D. et al. Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET\/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy. Lung Cancer 159, 45\u201355. https:\/\/doi.org\/10.1016\/j.lungcan.2021.06.024 (2021).","journal-title":"Lung Cancer"},{"key":"19362_CR23","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/1471-2407-13-158","volume":"13","author":"SH Jafri","year":"2013","unstructured":"Jafri, S. H., Shi, R. & Mills, G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): A retrospective review. BMC Cancer 13, 158. https:\/\/doi.org\/10.1186\/1471-2407-13-158 (2013).","journal-title":"BMC Cancer"},{"key":"19362_CR24","doi-asserted-by":"publisher","first-page":"6971","DOI":"10.1002\/cam4.4220","volume":"10","author":"H Imai","year":"2021","unstructured":"Imai, H. et al. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer. Cancer Med. 10, 6971\u20136984. https:\/\/doi.org\/10.1002\/cam4.4220 (2021).","journal-title":"Cancer Med."},{"key":"19362_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e37414","volume":"10","author":"R Taguchi","year":"2024","unstructured":"Taguchi, R. et al. Prognostic significance of LAT1 expression in pleural mesothelioma. Heliyon 10, e37414. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e37414 (2024).","journal-title":"Heliyon"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19362-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19362-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19362-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T09:15:39Z","timestamp":1760087739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19362-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["19362"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-19362-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"26 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board (IRB) of Saitama Medical University, International Medical Center (approval number: 20-125). The requirement for written informed consent was waived by the IRB due to the retrospective study design. In accordance with the IRB-approved protocol, an opt-out method was employed, and patients were given the opportunity to decline participation after public disclosure of study details. All procedures involving human participants were conducted in accordance with the ethical standards of the institutional review board and the 1964 Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35427"}}